Floatz logo

Polio/Rhinovirus Recombinant

Brain Tumor

Istari Oncology, Inc.Phase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

62 Active assets in the Brain Tumor cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BBB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bxcl501
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Nivolumab
InSightec
Phase 3BB

View all 50 →

Same molecule, other indications

Polio/Rhinovirus Recombinant is also rated in:

malignant gliomaDormant
B
Indicative ·
58 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →
melanomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →